Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.
Press releases published on June 11, 2025
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
GlobeNewswire
·
June 11, 2025
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm,” the “Company,” “we” or “us”), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the …
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
GlobeNewswire
·
June 11, 2025
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – …
Psychedelic Science 2025 Unveils Science, Studies & Trials Tracks Showcasing Next Generation in Brain Imaging, Clinical Trials, and Neuroplasticity
GlobeNewswire
·
June 11, 2025
• Sessions cover the latest updates in psychedelic neuroscience, from psilocybin’s effects on brain connectivity to trial design, clinical outcomes for PTSD, depression, addiction, and OCD, and the future of drug development through translational models …
Result of General Meeting
GlobeNewswire
·
June 11, 2025
June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of …
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
GlobeNewswire
·
June 11, 2025
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical …
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025
GlobeNewswire
·
June 11, 2025
Châtillon, France, le 11 juin 2025 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock …
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
GlobeNewswire
·
June 11, 2025
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, …
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
GlobeNewswire
·
June 11, 2025
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-100. The Reverse Stock Split …
Fortrea Names Anshul Thakral Chief Executive Officer
GlobeNewswire
·
June 11, 2025
DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Fortrea’s Board of Directors (the “Board”) named Anshul Thakral as Fortrea’s CEO, effective …
Allarity Therapeutics Announces Changes to Board of Directors
GlobeNewswire
·
June 11, 2025
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor— …
SRx Health Solutions Announces Management and Board Changes
GlobeNewswire
·
June 11, 2025
TAMPA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced the following management team and Board of Directors changes. Lionel Conacher, …
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
GlobeNewswire
·
June 11, 2025
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today …
Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
GlobeNewswire
·
June 11, 2025
BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, …
Abivax Announces Results of its June 6, 2025 Annual General Meeting
GlobeNewswire
·
June 11, 2025
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused …
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
GlobeNewswire
·
June 11, 2025
Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 months Acceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosing Data …
Chiesi Group ingår ett globalt licensavtal med Key2Brain AB för utveckling av terapier som passerar blod-hjärnbarriären för behandling av lysosomala upplagringssjukdomar
GlobeNewswire
·
June 11, 2025
Samarbetet kommer att utnyttja Key2Brains teknik för att ta fram enzymersättningsbehandlingar som passerar blod-hjärnbarriären för lysosomala upplagringssjukdomar Avtalet bygger på ett partnerskap som inleddes 2022 och stödjer fortsatt utveckling som drivs …
Chiesi Group sigla un accordo di licenza mondiale con Key2Brain AB per promuovere terapie che attraversano la barriera ematoencefalica per le malattie da accumulo lisosomiale
GlobeNewswire
·
June 11, 2025
La collaborazione sfrutterà la tecnologia di Key2Brain per sviluppare terapie enzimatiche sostitutive in grado di attraversare la barriera ematoencefalica per le malattie da accumulo lisosomiale L'accordo si basa su una partnership avviata nel 2022, a …
Global Electronic Health Record Market is Projected to Reach ~USD 54 Billion by 2032 | DelveInsight
GlobeNewswire
·
June 11, 2025
New York, USA, June 11, 2025 (GLOBE NEWSWIRE) -- Global Electronic Health Record Market is Projected to Reach ~USD 54 Billion by 2032 | DelveInsight The electronic health records market is experiencing robust growth, primarily driven by the increasing …
KFSHRC First in the Middle East to Implant AI-Powered Brain-Sensing Device for Treating Neurological Disorders
GlobeNewswire
·
June 11, 2025
RIYADH, Saudi Arabia, June 11, 2025 (GLOBE NEWSWIRE) -- In a landmark medical achievement, King Faisal Specialist Hospital …
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
GlobeNewswire
·
June 11, 2025
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025 NANTES, France, June 11, 6:30 PM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the cancellation of the convening of the mixed General Meeting initially …